ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS

BACKGROUND: Ivosidenib (AG-120, IVO) is a first-in-class oral inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), and vorasidenib (AG-881, VOR) is an oral, potent, brain-penetrant inhibitor of mIDH1/2. Both have been evaluated in glioma patients in ongoing phase 1 studies. In orthotopic glioma m...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Mellinghoff, Ingo, Cloughesy, Timothy, Wen, Patrick, Taylor, Jennie, Maher, Elizabeth, Arrillaga-Romany, Isabel, Peters, Katherine, Choi, Changho, Ellingson, Benjamin, Lin, Alexander, Thakur, Sunitha, Nicolay, Brandon, Lu, Min, Le, Kha, Yin, Feng, Tai, Feng, Schoenfeld, Steven, S Pandya, Shuchi, Hassan, Islam, Steelman, Lori, Clarke, Jennifer
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2019
Onderwerpen:
Adult Clinical Trials - Non-Immunologic
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847677/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.107
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items